Kratos Defense and Security Solutions (KTOS) – Demonstrates SATCOM Situational Awareness to an Operationally Secure Environment Using Commercial Resources


Kratos Demonstrates SATCOM Situational Awareness to an Operationally Secure Environment Using Commercial Resources

 

U.S. DoD and allied nations effort included roaming capability, electromagnetic interference support and sharing of data through Unified Data Library (UDL)

SAN DIEGO
April 26, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that they were the first to successfully exhibit an integrated SATCOM capability providing real-time Situational Awareness (SA) to an operationally secure environment. The demonstration included roaming among different networks to optimize wideband satellite communications (SATCOM) using Enterprise Management and Control (EM&C). EM&C is an effort by the 
DoD to plan, initiate, monitor and restore rapid, automated access to hybrid satellite constellations and networks, operated by various service providers.

The demonstration was part of a multi-national Joint All Domain Command and Control (JADC2) demonstration hosted by 
U.S. European Command, 
U.S. Air Forces in 
Europe and Air Forces Africa, and the 
Department of the Air Force Chief Architect Office. EM&C capabilities provided by Kratos and its industry partners highlighted a means for providing real-time satellite communication end-to-end connectivity status and operational readiness including spectral data, link and equipment status and detecting/geolocating electromagnetic interference (EMI). The event also highlighted a method to restore satellite service in response to interference and the capability to gather and fuse information from sensors and satellites through the 
Unified Data Library (UDL). The UDL is a 
U.S. government owned, cloud-enabled database accessible by the 
DoD and coalition partners. The capabilities available through EM&C are important as they support real-time warfighter communication across domains in times of war or conflict.

LTC Gary Thompson, Chief, Fighting SATCOM Capability Integration, SMC SATCOM Capability Integrator Office said, “This demonstration of EM&C helped the warfighters better understand the key satellite links used for communication and enabled precision identification, characterization, and troubleshooting of interference along the long-haul communication pathways. In addition, utilization of the UDL allowed the sharing of critical information across the joint forces for timely, fused situational awareness and lethality.”

EM&C is an important strategic goal of the military to effectively operate an integrated SATCOM enterprise by increasing assured SATCOM access for the warfighter with legacy and next-generation terminals. It improves the effectiveness of the DoD’s critical SATCOM infrastructure by enhancing resilience and giving more satellite link choices, reducing resource allocation times and improving bandwidth efficiency. Funding for the recent European demonstration was provided through the Air Force Life Cycle Management Center Advanced Battle Management System (ABMS) Broad Agency Announcement, of which Kratos is an award recipient. Kratos’ partnered with 
Knight Sky, LLC for terminal and 
Gateway equipment supporting the Flexible Terminal Interface (FTI), and 
SES Government Solutions (SES GS) to provide SATCOM capacity.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

electroCore Inc. (ECOR) – Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders


electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

 

ROCKAWAY, NJ
April 26, 2021 (GLOBE NEWSWIRE) —  — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that 
Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS) using the Company’s proprietary gammaCore device to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders (NCT04857281).

Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly.1 The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men.2 The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. 3

Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population.4

“The vagus nerve plays a key role in the regulation of nausea and vomiting,” commented Dr. Jay Pasricha, Professor of Medicine and Neurosciences and Director of the 
Johns Hopkins Center for Neurogastroenterology and principal investigator of the study. “Vagal modulation is currently thought to be a major component of the treatment benefit from an implanted gastric electrical stimulation (GES) device in patients with symptoms of gastroparesis and the planned proof of concept study explores whether a non-invasive hand-held device for vagal modulation can also be effective in reducing the need for traditional rescue medications for patients with unexplained nausea and vomiting.”

“We appreciate  Dr. Pasricha and his team selecting gammaCore (nVNS) for their study,” said  Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “gammaCore (nVNS) is the first non-invasive, handheld medical device proven to activate the vagus nerve by providing a patented mild electrical stimulation through the skin, and offers a potential alternative to GES that could eliminate significant risks of injury or illness associated with implantation.”

For more information, visit clinicaltrials.gov.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric
    • Patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the availability and impact of payer coverage, the potential of nVNS generally and gammaCore in particular to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.


1 Camilleri, M; Parkman HP; Shafi MA; Abell T; Gerson L. Clinical guideline: management of gastroparesis. 2013 Jan; 108 (1): 18-37.
2 Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR III. Prevalence of hidden gastroparesis in the community: the gastroparesis“iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.
3 Lacy BE, Crowell MD, Mathis C, Bauer D, Heinberg LJ. Gastroparesis: quality of life and health care utilization. J Clin Gastroenterol. 2018; 52: 20–24.
4 Harer, K; Pasricha PJ. Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND) An Update on Nomenclature, Pathophysiology and Treatment and Relationship to Gastroparesis. 2016 Dec; 14 (4): 410-419.


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Is ESG and B Corp. Investing Smart?

 


ESG, B Corps, and Investors

 

ESG investing and its accelerated rise show that people see purpose in putting their money where their values are or by following a growing investment trend – in many cases both. Companies are certainly aware of the movement and are working to establish themselves as fitting ESG investment criteria. Increasingly companies are altering the impact of their daily operations, and investors are noticing and reacting. According to the most recent biennial report from the United States Forum for Sustainable and Responsible Investment (US SIF), total US-domiciled assets under management employing ESG investing strategies increased 42 percent over the past two years, to $17 trillion in 2020, up from $12 trillion at the start of 2018.

The increased levels of adoption of ESG standards reporting have taken their cue from consumer demand, as customers and investors direct their dollars towards organizations that support this popular trend and away from others. Social governance and environmental standards are becoming the new norm as new companies develop in the mold and older companies innovate to capitalize on the movement of business towards these standards.

 Environmental, Social, Governance

MSCI has the tag line “Powering better investment for a better world,” their framework has currently taken the lead to shape understanding of the specific aspects of the operations that fall under “ESG”. The environmental (E) factors include measurements like carbon emissions in a company’s transport and logistics, the efficiency of their energy sources, and, particularly in the case of F&B companies, water usage. Social (S) factors relate to how the company treats its employees and diversity in leadership. Governance (G) indicators take a look at issues like share class structure, data security, and government structure.

 

 

In the past, it may have seemed that standards of accountability inhibited performance. However, as consumers and businesses alike adopt such standards, ESG rankings may actually point to the long-term viability of a company. According to research from MSCI, companies in the bottom ESG quintile have been twice as likely to suffer a catastrophic loss (over 95% cumulative loss) within three years.

 

B Corps

Many companies have also gone beyond the ESG standards and have now established themselves as B Corps. This certifies them as “benefit corporations” compliant with the standards of B Lab, a Pennsylvania-based business research organization that has set standards around corporate impact. According to B Lab, B Corp members in the U.K. have experienced an average YoY 14% growth rate, about 28x higher than the national average. For example, Leading B Corps rise are fast-moving consumer goods (FMCG or CPG) brands that grew 21% on average in 2017 compared to a national average of 3% across their respective sectors.

In 2016, MSCI downgraded Equifax’s ESG rating due to concerns about data privacy and cybersecurity. Almost exactly a year later, Equifax announced the data breach that compromised the personal information of 147 million people.

 

Take-Away

Beyond “greenwashing” and hollow corporate social responsibility, ESG frameworks have become increasingly integrated into business operations. Undoubtedly, a high ESG ranking also gives way to higher brand equity today and marketing campaigns can be designed around to appeal to the trend.  

In 2021, carrying a high ESG rating benefits a company in more ways than one. For investors, the trend is an added category worth reviewing; from an investment standpoint, this is where the attention is currently.

 

About the Author:

Laila Jiwani is a freelance writer specializing in topics related to social finance and international economic trends. Currently based in Dallas, Texas, she is an Erasmus Mundus Joint Master’s Graduate and has worked for economic development organizations in the U.S., Morocco, Kenya, Pakistan and Kyrgyzstan.

 

Suggested Reading:

Five Reasons Investors Increasingly Use ESG Standards

Expect 500,000 Fewer U.S. Births in 2021



Can Mining be Green and Sustainable?

Can Small Investors Compete With Wall Street?

 

Sources:

https://www.msci.com/who-we-are/about-us

https://bcorporation.net/

https://hbr.org/2016/06/why-companies-are-becoming-b-corporations

https://www.forbes.com/sites/jasonbisnoff/2020/12/14/esg-investing-a-sizzling-sector-that-will-get-even–hotter-under-president-biden/?sh=69ad80c23302

https://netimpactboston.wordpress.com/2015/03/12/b-corp-interview-anne-sherman-staach

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – electroCore Inc. (ECOR) – Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders


electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

 

ROCKAWAY, NJ
April 26, 2021 (GLOBE NEWSWIRE) —  — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that 
Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS) using the Company’s proprietary gammaCore device to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders (NCT04857281).

Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly.1 The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men.2 The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. 3

Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population.4

“The vagus nerve plays a key role in the regulation of nausea and vomiting,” commented Dr. Jay Pasricha, Professor of Medicine and Neurosciences and Director of the 
Johns Hopkins Center for Neurogastroenterology and principal investigator of the study. “Vagal modulation is currently thought to be a major component of the treatment benefit from an implanted gastric electrical stimulation (GES) device in patients with symptoms of gastroparesis and the planned proof of concept study explores whether a non-invasive hand-held device for vagal modulation can also be effective in reducing the need for traditional rescue medications for patients with unexplained nausea and vomiting.”

“We appreciate  Dr. Pasricha and his team selecting gammaCore (nVNS) for their study,” said  Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “gammaCore (nVNS) is the first non-invasive, handheld medical device proven to activate the vagus nerve by providing a patented mild electrical stimulation through the skin, and offers a potential alternative to GES that could eliminate significant risks of injury or illness associated with implantation.”

For more information, visit clinicaltrials.gov.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric
    • Patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the availability and impact of payer coverage, the potential of nVNS generally and gammaCore in particular to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.


1 Camilleri, M; Parkman HP; Shafi MA; Abell T; Gerson L. Clinical guideline: management of gastroparesis. 2013 Jan; 108 (1): 18-37.
2 Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR III. Prevalence of hidden gastroparesis in the community: the gastroparesis“iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.
3 Lacy BE, Crowell MD, Mathis C, Bauer D, Heinberg LJ. Gastroparesis: quality of life and health care utilization. J Clin Gastroenterol. 2018; 52: 20–24.
4 Harer, K; Pasricha PJ. Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND) An Update on Nomenclature, Pathophysiology and Treatment and Relationship to Gastroparesis. 2016 Dec; 14 (4): 410-419.


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Release – Kratos Defense and Security Solutions (KTOS) – Demonstrates SATCOM Situational Awareness to an Operationally Secure Environment Using Commercial Resources


Kratos Demonstrates SATCOM Situational Awareness to an Operationally Secure Environment Using Commercial Resources

 

U.S. DoD and allied nations effort included roaming capability, electromagnetic interference support and sharing of data through Unified Data Library (UDL)

SAN DIEGO
April 26, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that they were the first to successfully exhibit an integrated SATCOM capability providing real-time Situational Awareness (SA) to an operationally secure environment. The demonstration included roaming among different networks to optimize wideband satellite communications (SATCOM) using Enterprise Management and Control (EM&C). EM&C is an effort by the 
DoD to plan, initiate, monitor and restore rapid, automated access to hybrid satellite constellations and networks, operated by various service providers.

The demonstration was part of a multi-national Joint All Domain Command and Control (JADC2) demonstration hosted by 
U.S. European Command, 
U.S. Air Forces in 
Europe and Air Forces Africa, and the 
Department of the Air Force Chief Architect Office. EM&C capabilities provided by Kratos and its industry partners highlighted a means for providing real-time satellite communication end-to-end connectivity status and operational readiness including spectral data, link and equipment status and detecting/geolocating electromagnetic interference (EMI). The event also highlighted a method to restore satellite service in response to interference and the capability to gather and fuse information from sensors and satellites through the 
Unified Data Library (UDL). The UDL is a 
U.S. government owned, cloud-enabled database accessible by the 
DoD and coalition partners. The capabilities available through EM&C are important as they support real-time warfighter communication across domains in times of war or conflict.

LTC Gary Thompson, Chief, Fighting SATCOM Capability Integration, SMC SATCOM Capability Integrator Office said, “This demonstration of EM&C helped the warfighters better understand the key satellite links used for communication and enabled precision identification, characterization, and troubleshooting of interference along the long-haul communication pathways. In addition, utilization of the UDL allowed the sharing of critical information across the joint forces for timely, fused situational awareness and lethality.”

EM&C is an important strategic goal of the military to effectively operate an integrated SATCOM enterprise by increasing assured SATCOM access for the warfighter with legacy and next-generation terminals. It improves the effectiveness of the DoD’s critical SATCOM infrastructure by enhancing resilience and giving more satellite link choices, reducing resource allocation times and improving bandwidth efficiency. Funding for the recent European demonstration was provided through the Air Force Life Cycle Management Center Advanced Battle Management System (ABMS) Broad Agency Announcement, of which Kratos is an award recipient. Kratos’ partnered with 
Knight Sky, LLC for terminal and 
Gateway equipment supporting the Flexible Terminal Interface (FTI), and 
SES Government Solutions (SES GS) to provide SATCOM capacity.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Release – Avivagen (VIVXF)(VIV:CA) – Announces First Purchase Order from Large Integrated Producer in Asia


Avivagen Announces First Purchase Order from Large Integrated Producer in Asia

 

Ottawa, ON / Business Wire/ April 26, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances food production and supports immune function, thereby supporting general health and performance, is pleased to announce it has received its first purchase order from a large, integrated livestock producer in Thailand. The customer is a very large, well-known and respected swine and poultry producer in the region. This first purchase order from this customer, while modest in size, comes on the heels of several trials conducted by the customer with sows and piglets over the last nine months, whereby Avivagen’s OxC-betaTM Livestock consistently outperformed any and all competitive alternatives.

“We are very excited about this purchase from a very large and established market leading livestock producer in Thailand,” said Kym Anthony, Avivagen’s CEO.  “It is our belief that this first purchase, similar to our experience with UNAHCO, will lead to a growing rollout over the coming quarters and years by the customer and is likely to influence other producers in the region to adopt our product. The real world evidence of the benefits of our product are leading to more customer wins and growing adoption of our OxC-beta™ Livestock product.”

With annual livestock feed production in 2020 of 21million tonnes[i] Thailand is an important market opportunity for Avivagen, not only due to its size but the fact that Thailand’s largest livestock export market remains the European Union, where AGPs (Antibiotics as Growth Promoters) have been banned since 2010

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the future delivery of product based on the purchase order received, Avivagen’s expectations as to growth of its branding in certain jurisdictions, continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds,  and fulfillment of the order may be delayed beyond current expectation, or in the worst case cancelled, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Do Microcap Stocks Provide Better Diversification?

 


The Asset Allocation Role of Microcap Stocks

Investments in microcaps and even the smaller end of small-cap stocks have historically received less attention than mid-cap and large-cap companies. Noteworthy reasons for this include less scalability for large fund managers; also, microcaps often have less coverage on the research side. Another impactful oddity is that many worthwhile small companies lack a position in the “investment style box.”

Scalability, research and analysis, and not fitting neatly into the recognized style box all depress interest, awareness, and understanding of companies. Astute, individual investors can take advantage of the less talked about microcap sector and at the same time add diversification that could help key measures of performance.

 

Scalability

Imagine you’re an equity portfolio manager and have found the “secret sauce” to stock picking. You’ve backtested to 5 years with a $100,000 portfolio and the results have averaged 60% winners with a 42% average gain, and the losers and breakeven trades average just a 6% loss. With these results, your firm seeds an account with $10,000. and you now begin to test your methodology with live “ammo.” The methods driving your results include a mix of using trusted third-party fundamental analysis on small company stocks, then a common chart setup to find an entry point. After six months, your results aren’t quite as favorable relative to benchmarks as they had been, but still well ahead of the major market indexes.

The money management firm you work for has been reviewing your results and has now decided to create a fund around your investment style. They market the microcap fund heavily and over time, with very good performance, it attracts a few hundred million in assets.

With each large inflow to the fund, you find fewer opportunities because your original tested methods had a smaller universe, basically being nimble with large dollar amounts is more difficult. Even worse, whereas scaling into a position over the course of a few days with $2,000-$5,000 allowed decent price execution, doing the same with $75,000 – $250,000 or more tends to lift the stock price to the point where the trade may no longer be feasible if the size is available at all.

Unlike markets where having more to spend gives you price preference or negotiation power, with smaller, less liquid companies, small investors have an advantage. Your $10,000 “test” account with a 5% limit per name was able to outperform consistently. The exact same methods but with 100x the assets or more have watered down the success rate dramatically.

This is why there aren’t hundreds of funds run by large companies in this sector. The supply and demand issue would be too challenging. And since the big firms are the ones that push to get on TV to discuss their performance while they bombard you with paid ads, it is their products and stock picks that get far more coverage. This doesn’t mean there aren’t very successful small and microcap money managers, they don’t often get invited on to a major financial TV show as they aren’t big advertisers or even in need of adding hundreds of millions to any one of their portfolios.

 

 

Available Equity Research

The firms that do manage funds and portfolios that specialize in smaller companies rely on their understanding of the company fundamentals. This is another reason individuals may not be taking full advantage of smaller companies – the average investor simply doesn’t find much information written on them, and most investors aren’t capable of digging into the firm’s business model, their financials, or inviting themselves to meetings with management.

So, an asset management firm with in-house analysis can find stocks that are necessarily overlooked by large funds because of scalability, yet the stocks that represent great value can achieve outsized performance.  They are the players with “better” information and opportunity.

Fortunately for those transacting for smaller pools of money or even themselves, if they understand the value of investing in less correlated (vs. S&P 500) assets, they can now find well-presented research from veteran analysts with bulge-bracket firm pedigree. This top-tier analysis, coupled with low or no-cost brokerage trades, makes small company stocks well worth considering for a prudent portion of an overall asset mix.

 

Style Box

Since 1992 Morningstar and others that adopted the style box grid have taught investors to think of nine different categories of stock market investing. At the time Morningstar served those evaluating mutual funds, so the simplicity of boiling it down to a few columns made investor choices easy. However, the reduced complexity is oversimplified and ignores important sectors that can’t easily be scaled up into large mutual funds. There is a reason people are always encouraged to “think outside the box,” for many, it isn’t natural to look beyond what is put in front of them. If we round the style box up to a dozen options we could allow investors to visually see how they could improve diversification.

Fortunately, much of this is changing as self-directed investors become more sophisticated and begin to recognize that unless they’re allocating tens of millions of their own money, the case for microcap investments, both as a standalone asset class and for the role it can play as a less correlated allocation is compelling and worth considering as research becomes more widely available.

 

Take-Away

Individuals and small money managers aren’t being exposed to an option that may well suit them. The reasons are that media coverage is far less, the effort to uncover opportunities may be a bit higher, and they may be mentally stuck inside of a style box that was designed to serve the mutual fund industry. Resources available for people to manage their own portfolios have grown alongside technological advances.  Not all resources are of the same quality, but top-tier equity research and execution of trades now can be found without a cost to individuals.

Channelchek is a resource for exploring opportunities in the small and microcap space. With a growing list of companies covered by top-tier analysts, it is worth regular visits to the website to help find ideas to enhance and diversify your portfolio outside of the very dated box.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:

Money Supply is Like Caffeine for Stocks

IRA Investments and Small-Small Cap Stocks



Small-Cap Names in a Big Crypto Market

Managing Investment Portfolio Risk

 

Source:

https://en.wikipedia.org/wiki/Morningstar_Style_Box

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Analysis of a SPAC

 


Analysis of a Special Purpose Acquisition Company
(Part of a Channelchek Series on SPACs)

 

Special purpose acquisition companies (SPACs) are an increasingly popular vehicle for various transactions, including transitioning a business from a private company to a publicly traded corporation.  Some market participants believe that, through a SPAC transaction, a private company can become a publicly-traded company with a higher level of certainty as to pricing and control over deal terms when compared to a traditional initial public offerings (IPOs).

Analysis of a SPAC is part of a series of ongoing educational pieces published by Channelchek on the subject. From this edition, you should expect to gain a better understanding of:

  • Investor rights when a SPAC is in its shell company stage
  • Financial interests and motivations of SPAC sponsors
  • Evaluating investor options as it begins to de-SPAC
  • Warrants and possible impact on stockholders

Common Acquisition/Merger

Typically, a SPAC acquires or merges with a private company after a period of fewer than two years after the SPACs own introduction to the market as an IPO. Unlike a fully functioning business going public, a SPAC is non-operating and yet to be further defined aside from objective. Its primary asset is the cash which was proceeds from the IPO and perhaps contributions of founding members and sponsors.

Investing in a SPAC offering should involve a review of the potential success of the management team that formed the SPAC and the expectation that they will be able to acquire or combine with an operating business.  That acquisition or combination is known as the initial business combination; it is when the SPAC de-SPACs and is trading as other functioning public corporations do.  One consideration that must be understood is a SPAC may identify in its IPO prospectus a specific industry or business that it will target. However, it is not obligated to pursue a target in that suggested industry.

The Initial Business Combination

As the SPAC identifies the opportunity of an initial business combination, its founders and sponsors negotiate with the target before presenting for approval to SPAC shareholders. If approved by a majority vote, they execute on the takeover.  The transaction is commonly structured as a reverse merger where the operating company merges with and into the publicly traded SPAC.  The initial business may be structured in various ways; however, the combined company, once the transaction is executed, is a publicly-traded company and carries on the business it had been engaged in, while the SPAC designation ceases to exist (de-SPAC).

Evaluating an Investment in a SPAC  

Before the initial business combination, retain a copy of the prospectus and other reports (periodic and current field).  If there is third-party research available (quality research by credentialed providers), read and develop an understanding of the analyst’s evaluation. It’s important to comprehend the terms of any investment and the expectations of management.  While SPACs are generally uniform in structure and may be subject to certain minimum exchange listing requirements, it’s important to understand the specific features of any SPAC that you may commit money to. Part of this understanding includes the equity interests held by the sponsor and how they were derived (purchased versus nominal consideration).  Since the SPAC doesn’t have an operating history to evaluate, it’s important to evaluate the background of SPAC management, you should read and understand a SPAC’s IPO prospectus and periodic and current reports in the SEC’s EDGAR database.
 

SPACs generally invest the proceeds from the IPO in relatively safe, interest-bearing instruments. You’ll find the acceptable deposits or investments listed in the IPO prospectus, there are no regulatory guidelines for cash investments, so this section is important to visit.  Also, understand what anyb investment earnings are to be used for. SPACs often use the interest on the trust or escrow account assets to pay taxes.

 

 

Investor Redemption Option

A SPAC provides its investors with the option to redeem their shares rather than become a shareholder of the combined company.  Should the SPAC not be able to move forward and complete a business combination, shareholders are beneficiaries of the trust and are entitled to their pro-rata share of the amount left on deposit in the trust account. This is another area to focus on when reviewing the SPAC prospectus before committing to an investment. Review the IPO prospectus to understand the terms of the trust account, including your redemption rights and the circumstances in which cash may be released from the account.

If you purchased your shares on the open market at a cost different from the SPAC price (usually $10), your shares are redeemed at the same valuation as those that invested at the IPO price. If you own shares at a discount to the IPO price, you may profit (and have a tax situation). If you paid a premium, you will have your shares redeemed at a loss.

Consummation Period

Most
SPACs provide a two-year period for the management to identify and complete an initial business combination transaction.  The time frame is spelled out in the prospectus and should be verified. Some SPACs have opted for shorter periods.  The SPAC’s governing instruments may permit it to extend that time period – understand what you’re investing in.  In some governing documents, if a SPAC wants to extend the search period, it may be required to get shareholder approval.  There is a regulatory maximum if a SPAC lists its securities on an exchange; then it is required to complete an initial business combination within three years of its IPO. 

The current use of SPACs to acquire companies has the effect of increasing competition among SPACs and reducing the potential ideal targets. This should be weighed into your decision when tying up investment capital.

Secondary Trading

Be certain of the class of security that you’re putting in your portfolio. The initial public offering of a SPAC is often structured with securities that include common shares and warrants.  The warrants are contractual arrangements that provide registered holders the right to purchase from the company a specified number of additional shares of common stock in the future at a certain price, often a premium (out of the money) to the stock price when issued.

The initial SPAC unit will trade for some time after the IPO.  Over time, the SPAC common stock and warrants may begin trading on exchanges separately under unique trading symbols.  The SPAC generally files an 8K (Form 8-K ) and issues a press release to make interested parties aware when separate trading is to begin.  Investors who purchase SPAC securities after the IPO on the open market should be aware of whether they are purchasing units, common stock, or warrants.

The terms and stipulations of warrants are unique arrangements individual to each SPAC. It’s important to understand the contractual agreements as either an investor in common stock or in secondary warrants. The Terms will include how many shares warrant holders have the right to purchase (possible dilution of common shareholders) and as an investor how many shares a warrant would allow, the price at and period during which shares may be purchased, any circumstances under which the SPAC may be permitted to redeem the warrants, and the warrant expiration date. These terms and quantity can be found in the IPO prospectus for the SPAC.

 

 

Initial Business Combination Action Items

As the SPAC is successful in identifying a target for an initial business combination, shareholders of the SPAC can expect to receive a proxy statement to solicit shareholder approval. Shareholders will have the opportunity to vote on the transaction and as is standard in most SPAC documents, either remain a shareholder after the initial business combination or redeem their shares at its pro-rata amount as outlined earlier. In some cases, SPAC sponsors and affiliates may have enough votes to approve the transaction without a full shareholder vote.

This is a critical step, the successful (in terms of finding a target and transacting) SPAC now transitions from having assets that are a trust account to owning an operating company.  Depending on how you as an investor view the business being transacted on and whether it represents value to you, you have a window to be in or out at a pro-rata amount.

If the SPAC seeks shareholder approval of an initial business combination, it will provide shareholders with a proxy in advance of the shareholder vote.  In cases where the SPAC does not solicit the approval of public shareholders, because certain shareholders, such as the sponsor and its affiliates, hold enough votes to approve the transaction, it will provide shareholders with an Information Statement in advance of the completion of the initial business combination. 

The Proxy or Information Statement will contain information about the business of the company to be acquired, their financial statements, parties to the transaction, and the terms of the initial business combination transaction, including the capital structure of the combined entity. 

What Else?

In addition, the SPAC may require additional financings to fund the initial business combination, and those financings often involve the sponsors.  As a result, the interests of the sponsors may further diverge from your interests.  For example, additional funding from the sponsors may dilute your interest in the combined company or may be provided in the form of a loan or security that has different rights from your investments.

To learn more about a sponsor’s interests in a SPAC, review the Principal Stockholders and Certain
Relationships
and Related Party Transactions sections of a SPAC’s IPO prospectus.  You can learn more about an initial business combination and the sponsor’s interest from the Proxy Statement, Information Statement, or Tender Offer Statement.

 

You May Also Be Interested In:

The Lifecycle of a SPAC

Special Purpose Acquisition Corporations (SPAC) Attracting Investors



How PPI Impacts CPI Numbers

IRA Investments and Small-Cap Stocks


Stay up to date. Follow us:

           


Stay up to date. Follow us:

Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
[email protected]

Media Contact:
LaVoieHealthScience
Emmie Twombly
[email protected]
+1 857-389-6042

Release – Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
[email protected]

Media Contact:
LaVoieHealthScience
Emmie Twombly
[email protected]
+1 857-389-6042

Release – Energy Fuels (UUUU)(EFR:CA) – Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

 


Energy Fuels and Team from Penn State University Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

LAKEWOOD, Colo.April 23, 2021 /CNW/ – Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the U.S. Department of Energy (“DOE“) Office of Fossil Energy and National Energy Technology Laboratory has exercised their option to award Energy Fuels, working with a team from Penn State University, an additional $1.75 million to complete a feasibility study (“Feasibility Study“) on the production of rare earth element (“REE“) products from natural coal-based resources, as well as from other materials such as REE-containing ores like the natural monazite ore (“Monazite“) the Company is currently processing at its White Mesa Mill in Utah.

This award follows the DOE providing Energy Fuels a $150,000 contract in 2020 for the successful completion of a conceptual design for the same initiative, resulting in a total award to Energy Fuels of $1.9 million. The Feasibility Study is intended to support a cost estimate for the production of individually separated rare earth oxides and rare earth metals and alloys from coal-based resources or other resources, including Monazite, within the U.S., with a focus on REEs for the production of commodity and defense-related products.

Energy Fuels is already evaluating the potential to develop commercial REE separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, with the goal of fully integrating a commercial U.S. REE supply chain in the coming years. The Company’s work on the DOE Feasibility Study is expected to complement these efforts and has the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products in the U.S. in the coming years.

“We are pleased to continue our collaboration with the U.S. Department of Energy, as we work together to restore critical U.S. rare earth supply chains available for domestic manufacturing,” stated Mark S. Chalmers, President and CEO of Energy Fuels. “As we continue to ramp-up production of an intermediate rare earth product at the White Mesa Mill in Utah, we are moving forward with designing and developing the infrastructure needed to responsibly produce separated rare earth oxides and other products needed by the electric vehicle, renewable energy, defense and other domestic industries. Furthermore, we believe we can design our infrastructure to process feeds produced in the DOE program as well as the Monazite we are currently processing, for the recovery of uranium and REE products. We believe these kinds of collaborative public-private partnerships will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains.”

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com. 

Cautionary Note Regarding Forward-Looking Statements: This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States and Canada. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to the outcome of the Feasibility Study; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with regard to the cost of producing and separating REE carbonate at the White Mesa Mill; any expectation that the Company’s work on the Feasibility Study will complement the Company’s current efforts or have the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products; any expectation that the Company’s collaboration with DOE will restore critical U.S. rare earth supply chains available for domestic manufacturing; any expectation that the Company can design its infrastructure to process feeds produced in the DOE program as well as the Monazite it is currently processing, for the recovery of uranium and REE products; and any expectation that the Company’s collaboration with DOE will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: technical difficulties; processing difficulties and upsets; commodity price levels and fluctuations; competition from other facilities domestically and internationally; available supplies of coal-based or other resources that meet commercial specifications; the availability of long-term purchase and supply agreements; capital requirements; the ability of the White Mesa Mill to produce REE carbonate or other REE products that meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; permitting and licensing matters; and legal and regulatory challenges. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Investor Inquiries: Energy Fuels Inc., Curtis Moore, VP – Marketing and Corporate Development, (303) 974-2140, or Toll free: (888) 864-2125, [email protected], www.energyfuels.com

Release – CoreCivic (CXW) – Announces 2021 First Quarter Earnings Release and Conference Call Dates


CoreCivic Announces 2021 First Quarter Earnings Release and Conference Call Dates

 

BRENTWOOD, Tenn., April 23, 2021 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2021 first quarter financial results after the market closes on Wednesday, May 5, 2021.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 6, 2021, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 800-367-2403 in the U.S. and Canada, including the confirmation passcode 7487376. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:00 p.m. central time (2:00 p.m. eastern time) on May 6, 2021, through 1:00 p.m. central time (2:00 p.m. eastern time) on May 14, 2021. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8097453.

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. 

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
    Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Avivagen (VIVXF)(VIV:CA) – Announces Largest Single Customer Purchase Order


Avivagen Announces Largest Single Customer Purchase Order

 

 4 tonne order is the largest single shipment purchase in Avivagen’s history
 Purchase order represents more than 40% of previous fiscal year’s total volume

Ottawa, ON / Business Wire/ April 23, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce it has received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO. The purchase order is the largest single shipment purchase order of OxC-beta™ to date and represents a 10% increase in size over its previous record single shipment order.

“UNAHCO has been amongst the earliest adopters of OxC-beta™ for use in swine, and recently poultry, and its continued growth in order frequency and size is a clear indicator of the value that our product brings to the livestock feed production market,” said Kym Anthony, Chief Executive Officer, Avivagen Inc.  “We continue to add new applications and markets for OxC-beta™ worldwide that, taken together with our ongoing relationships with great and growing customers like UNAHCO, are providing dramatic growth potential and success for Avivagen. We also want to thank our colleagues who worked with the government in the Philippines to get this order cleared during challenging COVID-19 restrictions.”

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the future delivery of product based on the purchase order received, Avivagen’s expectations as to growth of its branding in certain jurisdictions, continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds,  and fulfillment of the order may be delayed beyond current expectation, or in the worst case cancelled, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com